Alpha-internexin as a brain-specific neurodegeneration marker: development and validation of a novel CSF assay
Rattachement africain : se, gb, us, in. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Alpha-internexin (AINX) is a type IV intermediate filament alongside the neurofilament triplet proteins and periferin. Despite its homologies, the key difference is that AINX is central nervous system-specific. The purpose of this study was to develop an immunoassay for cerebrospinal fluid (CSF) AINX, quantify it in patients with neurodegenerative diseases, and compare its diagnostic performance with neurofilament light (NfL). METHODS: Monoclonal antibodies were generated and characterized by immunoprecipitation followed by mass spectrometry and ELISA, for specificity to the target analyte and cross-reactivity. Single molecule array (Simoa) technology was the selected platform for assay development. The assay was validated according to pre-established parameters and AINX performance as a biomarker was tested in two independent cohorts (Gothenburg and University College London). RESULTS: Two highly specific antibodies were generated (B15 and Ina1) and used to develop a robust assay in all analytical validation parameters tested. The quantitative range of the assay was 0.137-140 pg/mL. In the Gothenburg cohort, AINX and NfL showed similar diagnostic performance, but the correlation between biomarkers was diagnosis dependent. In the University College London cohort, AINX and NfL showed similar trends across the different neurodegenerative diseases, with strong correlation between markers. CONCLUSIONS: We developed a highly sensitive and specific immunoassay for AINX in CSF. AINX showed similar diagnostic performance and high correlation with CSF NfL. Further research should focus on describing its role in specific disorders, as well as evaluate its potential as a blood-based biomarker.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Alpha-internexin as a brain-specific neurodegeneration marker: development and validation of a novel CSF assay
- Date Crossref
- 01/10/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Gothenburg Department of Psychiatry and Neurochemistry pays non établi dans la noticeUniversité ou école supérieure
-
Sahlgrenska University Hospital Clinical Neurochemistry Laboratory pays non établi dans la noticeÉtablissement de santé
-
UK Dementia Research Institute pays non établi dans la noticeStructure de recherche
-
University College London Institute of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
Huntington's Disease Association pays non établi dans la noticeOrganisation à but non lucratif
-
University of Wisconsin–Madison pays non établi dans la noticeUniversité ou école supérieure
-
Institute for Neurodegenerative Disorders pays non établi dans la noticeOrganisation à but non lucratif
-
National Hospital for Neurology and Neurosurgery pays non établi dans la noticeÉtablissement de santé
-
UCL Queen Square Institute of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
Indian Institute of Science Bangalore Centre for Brain Research pays non établi dans la noticeUniversité ou école supérieure
-
Dementia Research Centre Department of Neurodegenerative Disease pays non établi dans la noticeStructure de recherche
-
School of Medicine and Public Health Department of Pathology and Laboratory Medicine pays non établi dans la noticeUniversité ou école supérieure
Department of Psychiatry and Neurochemistry — University of Gothenburg, Clinical Neurochemistry Laboratory — Sahlgrenska University Hospital et UK Dementia Research Institute, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.